(503 days)
Not Found
Yes
The description mentions "proprietary algorithms which allow comparison to qualified databases containing images previously quoted by radiologists," which strongly suggests a machine learning approach for image analysis and comparison to a trained dataset. While the terms "AI" or "ML" are not explicitly used, the methodology described aligns with typical ML techniques for image-based classification or estimation.
No.
The device is intended to estimate BI-RADS breast density value to aid radiologists in assessment and provides adjunctive information, but it is explicitly stated that it "is not an interpretive or diagnostic aid" and does not treat or cure any condition.
No
The document explicitly states, "DenSeeMammo produces adjunctive information. It is not an interpretive or diagnostic aid when the final assessment of breast density category is made by an MQSA qualified interpreting physician." It aids radiologists but does not make the final diagnosis.
Yes
The device is described solely as software that analyzes digital mammograms and provides a breast density category. The description focuses on the software's functionality, input (DICOM files), and compatibility with operating systems, without mentioning any accompanying hardware components that are part of the medical device itself.
Based on the provided information, DenSeeMammo is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information about a person's health.
- DenSeeMammo's Function: DenSeeMammo analyzes medical images (digital mammograms) to estimate breast density. It does not analyze biological specimens.
- Intended Use: The intended use clearly states it's a software application for use with digital mammography systems to analyze images and aid radiologists in assessing breast density.
Therefore, DenSeeMammo falls under the category of a medical device, specifically a software medical device, but not an In Vitro Diagnostic device.
No
The provided text does not contain any explicit statements indicating that the FDA has reviewed, approved, or cleared a Predetermined Change Control Plan (PCCP) for this specific device. The 'Control Plan Authorized (PCCP) and relevant text' section explicitly states 'Not Found'.
Intended Use / Indications for Use
DenSeeMammo is a software application intended for use with digital mammography systems. DenSeeMammo estimates BI-RADS breast density value by analyzing processed digital 2D mammograms using a fully automated comparison procedure.
DenSeeMammo provides a Bl-RADS breast density 5th Edition category to aid radiologists in the assessment of breast density.
DenSeeMammo produces adjunctive information. It is not an interpretive or diagnostic aid when the final assessment of breast density category is made by an MQSA qualified interpreting physician. DenSeeMammo core software has been built and tested on OS X based computers.
DenSeeMammo graphical use interface software has been built and tested on Windows, OS X and Linux based computers.
DenSeeMammo is compatible for images obtained from GE Senographe Essentials systems.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
DenSeeMammo analyzes processed digital 2D mammograms in a fully automated comparison procedure that produces a BI-RADS breast density value.
DenSeeMammo handles processed images extracted from DICOM files as input.
DenSeeMammo core software has been built and tested on OS X based computers.
DenSeeMammo graphical user interface software has been built and tested on Windows, OS X and Linux based computers.
DenSeeMammo software is a component which accepts digital mammography images as an input. The software processes and analyses the image according to proprietary algorithms which allow comparison to qualified databases containing images previously quoted by radiologists.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
digital 2D mammograms
Anatomical Site
Breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Radiologists
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification bench testing of DenSeeMammo breast density software included:
- DenSeeMammo was run over twice on a data sets of images to test reproducibility.
- DenSeeMammo was run over on a sample of exams and left and right breast densities were compared to test reproducibility.
- DenSeeMammo results were compared to visual assessment from MQSA radiologists.
- DenSeeMammo was run over substantial data sets of images, which had been previously visually assessed by MOSA radiologists.
Clinical validation testing of DenSeeMammo breast density software included:
Beta site testing to assess the ability of physicians to successfully integrate the software into their existing systems as well as assess usability for target users.
All verification and validation testing was successful in that established acceptance criteria was met for all of the tests conducted.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 5, 2016
STATLIFE % Mrs. Robyn Bonnett Authorized Correspondent EPIDEMIO3D 50 Milk Street, 16th Floor BOSTON MA 02109
Re: K152009
Trade/Device Name: DENSEEMAMMO v1.0 Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: October 20, 2016 Received: October 24, 2016
Dear Mrs. Bonnett:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael O'Hara
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
For
Enclosure
2
Indications for Use
510(k) Number (if known) K152009
Device Name DENSEEMAMMO v1.0
Indications for Use (Describe)
DenSeeMammo is a software application intended for use with digital mammography systems. DenSeeMammo estimates BI-RADS breast density value by analyzing processed digital 2D mammograms using a fully automated comparison procedure.
DenSeeMammo provides a Bl-RADS breast density 5th Edition category to aid radiologists in the assessment of breast density.
DenSeeMammo produces adjunctive information. It is not an interpretive or diagnostic aid when the final assessment of breast density category is made by an MQSA qualified interpreting physician. DenSeeMammo core software has been built and tested on OS X based computers.
DenSeeMammo graphical use interface software has been built and tested on Windows, OS X and Linux based computers.
DenSeeMammo is compatible for images obtained from GE Senographe Essentials systems.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CER 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
1 Submitter Information
| Company Name: | STATLIFE |
|---|---|
| Company Address: | 39 RUE CAMILLE DESMOULINS |
| 94800 VILLEJUIF FRANCE | |
| Company Phone: | +33 660 848 385 |
| Company Facsimile: | +33 185 091 475 |
| Contact Person: | Stéphane Ragusa, CEO |
| Authorized Correspondent | |
| Phone | Valérie Hélin, Director of medical and regulatory affairs |
| +33 682 437 010 |
2 Trade name and Common name
| Trade Name: | DenSeeMammo |
|---|---|
| Software Version: | 1.0 |
| Common Name: | Imaging Software |
3 Device Classification
| Regulatory Class: | II |
|---|---|
| Classification Panel: | Radiology; |
| Product Code: | LLZ |
| Classification: | System, Image Processing, Radiological: 21 CFR § 892.2050 |
Identification of Predicate Device 4
The predicate device used for DenSeeMammo software is the following device: K102556 (October 7, 2010) – VOLPARA Imaging Software (MATAKINA Technology Limited)
5 Device Description
DenSeeMammo analyzes processed digital 2D mammograms in a fully automated comparison procedure that produces a BI-RADS breast density value.
DenSeeMammo handles processed images extracted from DICOM files as input.
DenSeeMammo core software has been built and tested on OS X based computers.
DenSeeMammo graphical user interface software has been built and tested on Windows, OS X and Linux based computers.
DenSeeMammo software is a component which accepts digital mammography images as an input. The software processes and analyses the image according to proprietary algorithms which allow comparison to qualified databases containing images previously quoted by radiologists.
4
For each patient it provides measures of BI-RADS breast density category. DenSeeMammo provides results per patient based on the maximum density category of the two breasts. The patient population is symptomatic and asymptomatic women undergoing mammography. The software does perform illustrative image display but only for illustrative purposes and not for interpretation or diagnostic.
6 Indications for Use
DenSeeMammo is a software application intended for use with digital mammography systems. DenSeeMammo estimates BI-RADS breast density value by analyzing processed digital 2D mammograms using a fully automated comparison procedure.
DenSeeMammo provides a BI-RADS breast density 5th Edition category to aid radiologists in the assessment of breast density.
DenSeeMammo produces adjunctive information. It is not an interpretive or diagnostic aid when the final assessment of breast density category is made by an MQSA qualified interpreting physician.
DenSeeMammo core software has been built and tested on OS X based computers.
DenSeeMammo graphical use interface software has been built and tested on Windows, OS X and Linux based computers.
DenSeeMammo is compatible for images obtained from GE Senographe Essentials systems.
7 Technological Characteristics
DenSeeMammo is a software that aims at assessing the breast density of a woman. The software use processed digital 2D mammograms in a fully automated comparison procedure that produces a BI-RADS breast density value. The software processes and analyses the image according to proprietary algorithms which allow comparison to qualified databases containing images previously quoted by radiologists. For each patient it provides measures of BI-RADS breast density category. DenSeeMammo provides results per patient based on the maximum density category of the two breasts.
The software works in a client-server mode and requires that the user computer is on the same local network as the server. Computations are made on the server part of the system that also provide the graphical user interface to display the results. A web browser is required to display the graphical user interface: to select the patients' images and to display the assessment of the breast density according to the BI-RADS standards and the similar images.
The software was developed using the Java-1.8 language as a 3-component web application (See 11.1 Components). The software was developed following an adapted version of the model - view controller software architectural pattern.
5
The device does not contact the patient, nor does it control any life-sustaining devices.
Substantial Equivalence 8
The comparison of the proposed device with the predicate device warrants a determination of substantial equivalence when considered in combination with the test results and technical information provided in this 510(k) Premarket Notification. Both devices are labeled as providing adjunctive information which is not an interpretive or diagnostic aid.
Table 1 Substantial Equivalence comparison table
| Characteristics | DENSEEMAMMO v1 | VOLPARA ™ Imaging Software
K102556 |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Classification | LLZ
892.2050 | LLZ
892.2050 |
| Software level of concern | Moderate | Moderate |
| Device type | Not an interpretive or diagnostic aid. | Not an interpretive or diagnostic aid. |
| Intended Use | DenSeeMammo is a software application intended for use with digital mammography systems.
DenSeeMammo estimates BI-RADS breast density value by analyzing processed digital 2D mammograms using a fully automated comparison procedure.
DenSeeMammo provides a BI-RADS breast density 5th Edition category to aid radiologists in the assessment of breast density.
DenSeeMammo produces adjunctive information. It is not an interpretive or diagnostic aid when the final assessment of breast density category is made by an MQSA qualified interpreting physician.
DenSeeMammo core software has been built and tested on OS X based computers. DenSeeMammo graphical use interface software has been built and tested on Windows, OS X and Linux based computers. | Volpara is a software application intended for use with digital mammography systems. Volpara calculates density as a ratio of fibroglandular tissue and total breast volume estimates.
Volpara provides these numerical values for each image to aid radiologists in the assessment of breast tissue composition.
Volpara produces adjunctive information. It is not an interpretive or diagnostic aid.
Volpara is a software application which runs on Windows or Linux-based computers. |
| Intended users | Radiologists | Radiologists |
| Patient population | Symptomatic and asymptomatic women undergoing mammography | Symptomatic and asymptomatic women undergoing mammography |
| Image source | Digital mammography images | Digital mammography images |
| Compatibility | GE Digital Mammography systems | GE and Hologic Digital Mammography systems |
3 | Page
6
| Characteristics | DENSEEMAMMO v1 | VOLPARA TM Imaging Software
K102556 |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Anatomical area | Breast | Breast |
| Assessment scope | Provides results per patient based on
the maximum density category of the
two breasts | Provides results per image (per each
breast) |
| Assessment type | Comparison to qualified databases
containing images previously quoted by
MQSA radiologists using ACR BI-RADS V
recommendations | Volumetric |
| Measures provided | For each breast: BI-RADS V breast
density category
For each patient: BI-RADS V breast
density value | For each breast:
→ Volume of fibro glandular tissue
→ Volume of breast
→ Breast density
For each patient:
VOLPARA density grade/BIRADS breast
density |
| Operating environment | Software core: OS X based computers
Software graphical user interface:
Windows, OS X or Linux based
computers | Windows or Linux-based computers |
| Deployment | Stand-alone computer | Stand-alone computer |
9 Performance Testing
The DenSeeMammo software has been verified and validated according to the company's design control process and particularly according the IEC 62304 standard. A risk analysis compliant with ISO 14971 has been provided. Software testing included both unit level and integrated system level testing.
Verification bench testing of DenSeeMammo breast density software included:
-
DenSeeMammo was run over twice on a data sets of images to test reproducibility.
-
DenSeeMammo was run over on a sample of exams and left and right breast densities were compared to test reproducibility.
-
DenSeeMammo results were compared to visual assessment from MQSA radiologists.
-
DenSeeMammo was run over substantial data sets of images, which had been previously visually assessed by MOSA radiologists.
7
Clinical validation testing of DenSeeMammo breast density software included:
Beta site testing to assess the ability of physicians to successfully integrate the software into their existing systems as well as assess usability for target users.
All verification and validation testing was successful in that established acceptance criteria was met for all of the tests conducted.
10 General Safety and Effectiveness Concerns
The device contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of this device. Risk management is ensured via a risk analysis, which is used to identify potential hazards. These potential hazards are controlled via software development, verification and validation testing.
11 Conclusions Drawn from Studies
The results demonstrate that the DenSeeMammo device is substantially equivalent to the predicate device in function and indications for use.